This document discusses the potential utility of biomarkers for diagnosing and prognosing sepsis. It begins by explaining why improving diagnostic and prognostic tools for sepsis is important, as it is a leading cause of death in ICU patients. It then discusses how early detection and treatment are paramount but current detection strategies are limited. The document introduces the biomarker paradigm for sepsis, where biomarkers can identify inflammation, coagulation, tissue damage and repair processes to better stratify severity and prognosticate outcomes. Several candidate biomarkers are discussed, such as procalcitonin, cytokines, chemokines, and pentraxin 3. The document considers how biomarkers may help with diagnosis, prognostication, and identifying high-risk patients and treatment response. It concludes the future